Elena Ratner, MD

Associate Professor of Obstetrics, Gynecology and Reproductive Sciences; Co-Chief, Section of Gynecologic Oncology

Research Departments & Organizations

Obstetrics, Gynecology & Reproductive Sciences: Discovery to Cure | Reproductive Sciences: Discovery to Cure Internship; Ratner Lab

Yale Cancer Center: Cancer Prevention and Control

Office of Cooperative Research

Research Summary

Dr. Ratner's laboratory is working on new targeted drugs for ovarian cancer in order to provide patients with truly personalized care. Her work additionally focuses on reversing chemotherapy resistance in ovarian and uterine cancers. 

Extensive Research Description

Dr. Ratner's laboratory is working on new targeted drugs for ovarian cancer in order to provide patients with truly personalized care. Her work additionally focuses on reversing chemotherapy resistance in ovarian and uterine cancers. 

Clinical Trials

Conditions Study Title
Cervix A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
Ovary Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer
Ovary ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Corpus Uteri A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Ovary A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Corpus Uteri A phase II evaluation of pembrolizumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent hypermutated/ultramutated endometrial cancer identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP), A Pilot Study
Anus, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Cervix, Urinary Bladder NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Cervix Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy
Corpus Uteri, Other Female Genital A Phase II Evaluation of Afatinib

Edit this profile

Contact Info

Elena Ratner, MD
Mailing Address
Obstetrics, Gynecology & Reproductive SciencesPO Box 208063
New Haven, CT 06520-8063